Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Oct 31 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced the acquisition of the UK-based LiqMeds Group through its subsidiary Zydus Pharmaceuticals UK Limited. The acquisition focuses on the development and supply of oral liquid products for global markets, with an upfront payment involved. This transaction is expected to be accretive to earnings per share from the first year of acquisition. The Managing Director emphasized the growth potential in the oral liquids market, particularly for geriatric and pediatric patients.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases